Molecular Partners Ag ADR (MOLN)

🚨 Major Monday earnings releases after bell: $SMTC after bell $HEI after bell $FSCO after bell $MOLN after bell $SNT after bell

"Heads up alert! Upcoming earnings on Monday, 8/25/2025 for $MOLN Neutral (5.2) --- MOLN Financial Analysis: Molecular Partners AG, known by its ticker MOLN, operates within the biotechnology sector, focusing on the development of novel therapeutic approaches, particularly tetraspecific antibodies. Recent analyses suggest a steady trajectory for the company's financial health, with key metrics indicating a cautious yet promising outlook for investors. The company's price-to-earnings (P/E) ratio currently stands in line with industry averages, reflecting a market valuation that is neither overly inflated nor undervalued. Earnings per share (EPS) growth has shown moderate improvement, supported by consistent R&D expenditure aimed at advancing its unique DARPin® technology platform. Revenue forecasts point towards incremental growth, bolstered by ongoing partnerships and the potential for new market entries as regulatory approvals for its tetraspecific antibodies are anticipated by 2029. Compared to industry peers like Innate Pharma and ModeX Therapeutics, Molecular Partners exhibits a strong innovative edge, although its financial metrics suggest a need for continued strategic alliances and successful clinical outcomes to maintain competitive standing. Upcoming Earnings Report: The upcoming earnings report for Molecular Partners is highly anticipated, with expectations centered around an update on clinical trial progress and strategic partnerships. Historically, the company has demonstrated a pattern of meeting or slightly exceeding analyst consensus estimates, which has contributed to moderate stock price stability. Current analyst consensus estimates suggest cautious optimism, with projected EPS reflecting the ongoing investment in their R&D pipelines. The potential impact of the earnings report on the stock will largely depend on the disclosed progress of its therapeutic candidates and any strategic developments that could accelerate market entry or expand its commercial footprint. Sector Performance: Molecular Partners is part of the broader biotechnology sector, which has experienced a mixed performance landscape recently. The sector is characterized by rapid innovation and high volatility, driven by regulatory decisions and breakthrough therapies. Despite some headwinds, including regulatory scrutiny and funding challenges, the biotechnology sector continues to outperform many traditional sectors in terms of growth potential, underscored by a robust pipeline of novel therapeutics and increasing collaborations. As a player in this dynamic environment, Molecular Partners stands to benefit from the sector's overall growth trajectory, provided it can navigate the inherent risks associated with clinical development and market competition. - Funds were net buyers of $MOLN during the previous reporting quarter. - Funds with large holdings in $MOLN include: - Suvretta Capital Management LLC, MV: $8MM. Fund Rank: 78% www.suvcap.com - BVF Partners LP, MV: $5MM. Fund Rank: 71% www.bvflp.com - Last 10 days performance: -5% - Last 30 days performance: -10% - Last 90 days performance: -11% Some of the latest news articles: - Title: Tetraspecific Antibodies Market Research 2025-2029 | Molecular Partners, Innate Pharma, and ModeX Therapeutics Lead Innovations for Oncology and Autoimmune Publication Date: 8/6/2025 8:24:00 AM, Source: yahoo URL: https://finance.yahoo.com/news/tetraspecific-antibodies-market-research-2025-082400027.html?.tsrc=rss Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."

$MOLN pt 4.4

$GTBP $ALXO $ERAS $MOLN $SLDB

$MOLN Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 Molecular Partners and Orano Med have nominated MP0726, a Radio-DARPin targeting mesothelin (MSLN), for development under their strategic partnership. Designed for the treatment of ovarian cancer, MP0726 has shown promising in vivo tumor accumulation, selective MSLN binding, and a favorable tumor-to-kidney ratio. Preclinical data will be presented at the 2025 SNMMI Annual Meeting in New Orleans.

$MOLN $MOLN news, maybe add to monday watchlist.

🚀 Hot IND Filings Ahead! 🚀 Watch these biotech plays gearing up for IND filings in H1 & Mid-2025: • $GTBP GTB-5550 (solid tumors) – PoA 10% • $ALXO ALX2004 (EGFR ADC) – PoA 25% • $ERAS ERAS-0015 (NRAS melanoma) – PoA 12% • $MOLN MP0712 (DLL3 target) – PoA 12% • $SLDB SGT-501 (gene therapy for CPVT) – PoA 30% Early-stage catalysts worth tracking for potential moves! Get full details & real-time updates at biopharmawatch.com #Biotech #INDFilings #Catalysts #BiotechInvesting

$MOLN Molecular Partners to preent updated data from MP0533 trial at EHA congress Molecular Partners announced a poster presentation with updated data from a Phase 1/2a trial of the tetraspecific T-cell engager MP0533 in relapsed/refractory acute myeloid leukemia, at the 30th European Hematology Association Congress, taking place in Milan on June 12-15. The poster outlines the impact of accelerated step-up dosing regimen of MP0533 on exposure and clinical responses in cohort 8, providing the rationale for further optimization to the dosing regimen implemented in the ongoing cohort 9. Data from cohort 8 show that 3 of 8 evaluable patients achieved a clinical response after the first cycle, with one patient achieving a complete response and two patients a complete response with partial hematologic recovery as best overall response. Two patients maintained a response for more than 3 months and one patient remains on treatment, maintaining a response beyond 6 months at the time of data cutoff. Cohort 8 implemented a higher starting dose than cohorts 1-7, and the inclusion of an additional day of dosing, reaching the target dose by day 12, as opposed to day 15 previously. Cohort 8 data indicate that patients maintained exposure to MP0533 for a longer period of time within the predicted therapeutic range through the accelerated step-up dosing scheme, within the first cycle. Data show that patients reached over 4 days of relevant exposure, with 5 out of 8 patients displaying greater than 50% blast reduction. MP0533 shows an acceptable safety profile after adjustment of the target dose in cohort 8. In cohorts 1-7, where step-up dosing reached target dose by day 15, exposure to predicted therapeutic doses was limited to roughly 2 days in the first cycle, most likely due to target-mediated-drug deposition. This prior treatment protocol, despite demonstrating initial blast reductions in ~30% of patients, resulted in limited responses. Based on the encouraging antitumor activity observed in cohort 8, the amended protocol for cohort 9 and beyond includes further acceleration of the step-up dosing to reach therapeutically-relevant doses faster, increased frequency of dosing for higher cumulative MP0533 exposure, and the introduction of anti-CD20 premedication to mitigate loss of exposure, with the objective to further increase the depth and duration of responses in patients. Cohort 9 is currently dosing patients and initial data from the amended dosing scheme are expected in H2 2025. Additionally, future study cohorts will evaluate the combination of azacitidine/venetoclax with MP0533.

$MOLN https://prismmarketview.com/molecular-partners-cuts-costs-extends-cash-runway-into-2028-while-advancing-key-clinical-programs/